Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.
Heinzelbecker J, Spieler N, Kuehn M, Fischer C, Volkmer B, von Rundstedt F, Albers P, Becht E, Bannowsky A, Weber HM, Hofmann R, Müller M, Langbein S, Steiner G, Retz M, Kamradt J, Wagenpfeil G, Wellek S, Lehmann J, Stoeckle M.
Heinzelbecker J, et al. Among authors: weber hm.
Urol Oncol. 2023 Aug;41(8):356.e19-356.e30. doi: 10.1016/j.urolonc.2023.04.016. Epub 2023 May 16.
Urol Oncol. 2023.
PMID: 37198025
Clinical Trial.